Le Bail N - Search Results

1

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. de Gramont A, et al. Among authors: le bail n. J Clin Oncol. 2000 Aug;18(16):2938-47. doi: 10.1200/JCO.2000.18.16.2938. J Clin Oncol. 2000. PMID: 10944126 Corrected and republished. Clinical Trial.

2

Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer.

de Gramont A, Vignoud J, Tournigand C, Louvet C, André T, Varette C, Raymond E, Moreau S, Le Bail N, Krulik M. de Gramont A, et al. Among authors: le bail n. Eur J Cancer. 1997 Feb;33(2):214-9. doi: 10.1016/s0959-8049(96)00370-x. Eur J Cancer. 1997. PMID: 9135491 Clinical Trial.

3

[Oxaliplatin, folinic acid and 5-fluorouracil (folfox) in pretreated patients with metastatic advanced cancer. The GERCOD].

de Gramont A, Tournigand C, Louvet C, André T, Molitor JL, Raymond E, Moreau S, Vignoud J, Le Bail N, Krulik M. de Gramont A, et al. Among authors: le bail n. Rev Med Interne. 1997;18(10):769-75. doi: 10.1016/s0248-8663(97)89966-3. Rev Med Interne. 1997. PMID: 9500010 Clinical Trial. French.

4

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.

Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Lévi F. Giacchetti S, et al. Among authors: le bail n. J Clin Oncol. 2000 Jan;18(1):136-47. doi: 10.1200/JCO.2000.18.1.136. J Clin Oncol. 2000. PMID: 10623704 Clinical Trial.

5

Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.

Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG. Rothenberg ML, et al. Among authors: le bail n. J Clin Oncol. 2003 Jun 1;21(11):2059-69. doi: 10.1200/JCO.2003.11.126. J Clin Oncol. 2003. PMID: 12775730 Clinical Trial.

6

Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer.

de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. de Gramont A, et al. Among authors: le bail n. J Clin Oncol. 2023 Nov 20;41(33):5080-5089. doi: 10.1200/JCO.22.02773. J Clin Oncol. 2023. PMID: 37967516

7

Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.

Catimel G, Verweij J, Mattijssen V, Hanauske A, Piccart M, Wanders J, Franklin H, Le Bail N, Clavel M, Kaye SB. Catimel G, et al. Among authors: le bail n. Ann Oncol. 1994 Jul;5(6):533-7. doi: 10.1093/oxfordjournals.annonc.a058908. Ann Oncol. 1994. PMID: 7918125 Free article. Clinical Trial.

8

Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion.

Bissett D, Setanoians A, Cassidy J, Graham MA, Chadwick GA, Wilson P, Auzannet V, Le Bail N, Kaye SB, Kerr DJ. Bissett D, et al. Among authors: le bail n. Cancer Res. 1993 Feb 1;53(3):523-7. Cancer Res. 1993. PMID: 8093854 Clinical Trial.

9

Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion.

Extra JM, Rousseau F, Bruno R, Clavel M, Le Bail N, Marty M. Extra JM, et al. Among authors: le bail n. Cancer Res. 1993 Mar 1;53(5):1037-42. Cancer Res. 1993. PMID: 8094996 Clinical Trial.

10

[Comparison between single-dose and hyperfractionated total-body irradiation for the conditioning of allogenic grafts of the bone marrow. A retrospective study of 54 patients with malignant hematologic diseases].

Baume D, Cosset JM, Pico JL, Girinski T, Le Bail N, Nabholtz JM, Benhamou E, Dutreix J, Hayat M. Baume D, et al. Among authors: le bail n. Bull Cancer. 1988;75(4):361-72. Bull Cancer. 1988. PMID: 3289643 French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

16 results

Search Page